

## Company profile

Fact Sheet (Status: Feb 03, 2012)

New Value invests directly in private, upwardly mobile companies located in Switzerland and the German-speaking region whose market and growth potential exceeds the average. As an investment company, New Value provides the venture capital to promote innovative business models, and it supports them until they achieve success on the market. Its portfolio includes companies at varying stages of their corporate development, from the start-up phase up to the time they become established SMEs. A broad approach is intentionally pursued. New Value's portfolio includes companies from the Cleantech and Healthcare sectors.

When selecting its portfolio targets, New Value places great emphasis on ethical business plans and good corporate governance. New Value regards criteria such as commitment to meaning, social compatibility and environmental sustainability as decisive competitive advantages that have a quality-promoting impact on a company's products and services and thus permit it to attain above-average potential in terms of share value appreciation.

New Value will focus on further developing its existing portfolio companies in the cleantech and health care sectors. New Value plans to guide its investments into the next development phase and then realize them at maximum value.

## Board of Directors

- Thomas Keller (P)
- Paul Santner (VP)

- Gerhart Isler
- Jan Larsson

## Share chart



## Financial calendar

Aug 15, 2012 General Assembly New Value AG

## Shareholder structure

19.9% Personalvorsorgekasse Stadt Bern

## Stock fundamentals

ISIN	CH0010819867	Branch	Investment Company	No. of shares	3,287,233 nominal shares per CHF 10.00
Valorenummer	1081986	Country	Schweiz	Stock exchanges	SIX Swiss Exchange, XETRA, Frankfurt, Stuttgart, Duesseldorf, Berlin, Munich
WKN	552932	Index	LPX Composite® Index		
Share type	Namenaktie	NAV per Share	CHF 17.94		
Bloomberg Code	N7V@GR				
Ticker	NEWN(CH), N7V(DE)				

## Investments

The biggest positions and their portfolio shares (per 31.10.2011):

**Cleantech:**

Solar Industries AG	Solar Technology	19,7%
Silentsoft SA	Energy Efficiency	8,9%
Mycosym International AG	Plant Technology	2,8%

**Healthcare:**

Swiss Medical Solution AG	in-vitro diagnostic	15,2%
Idiag AG	Diagnostics, Rehabilitation	11,0%
QualiLife SA	Access Technology	8,2%
Sensimed SA	Diagnostics	5,9%

## Key figures

Annual figures	2006	2007	2008	2009	2010
<b>in CHF</b>					
Total income from investments and loans	7,133,124	27,673,662	6,655,235	26,768,738	6,332,951
Total expenses from investments and loans	(1,582,256)	(2,727,857)	(17,656,462)	(13,689,214)	(13,981,837)
Total operating expenses	(2,140,008)	(2,685,999)	(2,853,167)	(2,711,977)	(2,685,803)
Total financial income and expenses	44,750	49,934	(134,431)	(352,191)	29,148
Earnings before taxes	3,455,610	22,309,740	(13,988,825)	10,015,356	(10,305,543)
Consolidated annual loss/win	3,455,610	22,309,740	(13,988,825)	10,015,356	(10,305,543)
Loss/win per share	1.21	7.78	(4.91)	3.20	(3.54)

## NEW VALUE AG

NEW VALUE AG  
 Gartenstrasse 36  
 8002 Zürich  
 Schweiz

Tel: +41 44 202 12 70  
 E-Mail: [info@newvalue.ch](mailto:info@newvalue.ch)  
[www.newvalue.ch](http://www.newvalue.ch)

## Investor Relations

**Thomas Keller**  
 President of the Board  
 E-Mail: [info@newvalue.ch](mailto:info@newvalue.ch)

Tel: +41 44 202 12 70